{"id":"gw406381","safety":{"commonSideEffects":[{"rate":null,"effect":"Headache"},{"rate":null,"effect":"Nausea"},{"rate":null,"effect":"Diarrhea"}]},"_chembl":{"chemblId":"CHEMBL364804","moleculeType":"Small molecule","molecularWeight":"393.47"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"P2X7 receptor antagonism reduces ATP-mediated activation of immune cells, particularly macrophages and microglia, thereby suppressing pro-inflammatory cytokine release and neuroinflammation. This mechanism is thought to be beneficial in conditions characterized by excessive inflammation and immune activation, particularly in the central nervous system.","oneSentence":"GW406381 is a selective antagonist of the P2X7 receptor, an ATP-gated ion channel involved in inflammatory and immune responses.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T00:47:35.549Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Rheumatoid arthritis"},{"name":"Neuropathic pain"}]},"trialDetails":[{"nctId":"NCT00373243","phase":"PHASE1","title":"A Study Of GW406381 In Volunteers With Moderate Hepatic Impairment","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2005-10-19","conditions":"Pain","enrollment":24},{"nctId":"NCT00113308","phase":"PHASE3","title":"COX-2 Inhibitor Study In Patients With Rheumatoid Arthritis","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2005-06","conditions":"Arthritis, Rheumatoid","enrollment":2208},{"nctId":"NCT00120900","phase":"PHASE3","title":"Evaluation of GW406381 in Treating Adults With Osteoarthritis Of The Knee","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2005-05","conditions":"Osteoarthritis, Knee","enrollment":1340},{"nctId":"NCT00114049","phase":"PHASE3","title":"Dental Pain (Following Third Molar Tooth Extraction) Study","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2004-12","conditions":"Dental Pain, Surgery, Dental","enrollment":300},{"nctId":"NCT00279032","phase":"PHASE1","title":"GW406381 In Patients With Peripheral Nerve Injury","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2003-09","conditions":"Hyperalgesia, Neurodynia, Pain","enrollment":40}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":8,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"GW406381","genericName":"GW406381","companyName":"GlaxoSmithKline","companyId":"gsk","modality":"Small molecule","firstApprovalDate":"","aiSummary":"GW406381 is a selective antagonist of the P2X7 receptor, an ATP-gated ion channel involved in inflammatory and immune responses. Used for Rheumatoid arthritis, Neuropathic pain.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":1,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}